Calmark receives order from Mediq in Sweden
Calmark Sweden AB (publ) announces today that the Company’s Swedish distributor Mediq has places its first clinical order for instruments and Neo-Bilirubin test cassettes. The economic value of today's order is of minor importance, but it is important from a launch perspective.
As previously disclosed, an exclusive distributor agreement has been signed with the company Mediq Sverige AB regarding marketing and sales of Calmark's Neo products in Sweden. A marketing and launch plan has been drawn up and Mediq has now placed a first clinical order.
"I am glad that our Neo products will also start to be used in Sweden," says Magdalena Tharaldsen, Director International Business Development at Calmark. "I look forward to soon receiving feedback from the Swedish healthcare system on how Neo-Bilirubin contributes to more effective diagnostics for neonatal jaundice."
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 02-05-2023 10:28 CET.
For more information about Calmark Sweden AB, please contact:
Camilla Arneving, Acting CEO
Telefon: +46 (0)10 204 01 50
E-post: camilla.arneving@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.